# Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

Study · id `cardio:ct-nct05963568` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05963568](<https://clinicaltrials.gov/study/NCT05963568>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05963568

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT05963568. Randomized; single masking; primary purpose prevention. Start 2026-04-01 (actual); primary completion 2029-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT05963568, source copy `cardio:ctgov-nct05963568-2026-07-06`, retrieved 2026-10-26)
- Started: 2026-04-01 (actual) (ClinicalTrials.gov record NCT05963568, source copy `cardio:ctgov-nct05963568-2026-07-06`, retrieved 2026-10-26)
- Primary completion: 2029-01-31 (anticipated) (ClinicalTrials.gov record NCT05963568, source copy `cardio:ctgov-nct05963568-2026-07-06`, retrieved 2026-10-26)
- Completion: 2029-02-01 (anticipated) (ClinicalTrials.gov record NCT05963568, source copy `cardio:ctgov-nct05963568-2026-07-06`, retrieved 2026-10-26)
- Countries: Benin; Ghana; Nigeria; Tanzania (ClinicalTrials.gov record NCT05963568, source copy `cardio:ctgov-nct05963568-2026-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05963568-2026-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)
- Condition: Stroke
- Condition: Medication Adherence
- Intervention (Drug): Polycap
- Lead sponsor: Northern California Institute of Research and Education
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Northern California Institute of Research and Education (`cardio:org-northern-california-institute-of-research-and-education`)

## Provenance

Content hash: 32ea2c0d3bde52230546d804c436aa39d6f32bf23ef532384559784f101e2100
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
